tetano
Editor, Senior Moderator
J Pediatr Hematol Oncol
. 2023 Feb 20.
doi: 10.1097/MPH.0000000000002644. Online ahead of print.
Outcomes of Coronavirus Disease 2019 Infection in Children and Adolescents With Cancer in Canada: Population-based Study and Systematic Review
Catherine Mark[SUP] 1 [/SUP], Paul Gibson[SUP] 2 [/SUP], Lucie Lafay-Cousin[SUP] 3 [/SUP], Georgina Martin[SUP] 4 [/SUP], Sapna Oberoi[SUP] 5 6 [/SUP], Lucie Pecheux[SUP] 7 8 [/SUP], Shahrad R Rassekh[SUP] 9 [/SUP], Alexandra Zorzi[SUP] 10 [/SUP], Sarah Alexander[SUP] 1 [/SUP], Sumit Gupta[SUP] 1 [/SUP]
Affiliations
Abstract
Published outcomes for children with cancer with coronavirus disease 2019 (COVID-19) have varied. Outcome data for pediatric oncology patients in Canada, outside of Quebec, have not been reported. This retrospective study captured patient, disease, and COVID-19-related infectious episode characteristics and outcome data for children, 0 to 18 years, diagnosed with a first COVID-19 infection between January 2020 to December 2021 at 12 Canadian pediatric oncology centers. A systematic review of pediatric oncology COVID-19 cases in high-income countries was also undertaken. Eighty-six children were eligible for study inclusion. Thirty-six (41.9%) were hospitalized within 4 weeks of COVID-19; only 10 (11.6%) had hospitalization attributed to the virus, with 8 being for febrile neutropenia. Two patients required intensive care unit admission within 30 days of COVID-19 infection, neither for COVID-19 management. There were no deaths attributed to the virus. Of those scheduled to receive cancer-directed therapy, within 2 weeks of COVID-19, 20 (29.4%) experienced treatment delays. Sixteen studies were included in the systematic review with highly variable outcomes identified. Our findings compared favorably with other high-income country's pediatric oncology studies. No serious outcomes, intensive care unit admissions, or deaths, in our cohort, were directly attributable to COVID-19. These findings support the minimization of chemotherapy interruption after COVID-19 infection.
. 2023 Feb 20.
doi: 10.1097/MPH.0000000000002644. Online ahead of print.
Outcomes of Coronavirus Disease 2019 Infection in Children and Adolescents With Cancer in Canada: Population-based Study and Systematic Review
Catherine Mark[SUP] 1 [/SUP], Paul Gibson[SUP] 2 [/SUP], Lucie Lafay-Cousin[SUP] 3 [/SUP], Georgina Martin[SUP] 4 [/SUP], Sapna Oberoi[SUP] 5 6 [/SUP], Lucie Pecheux[SUP] 7 8 [/SUP], Shahrad R Rassekh[SUP] 9 [/SUP], Alexandra Zorzi[SUP] 10 [/SUP], Sarah Alexander[SUP] 1 [/SUP], Sumit Gupta[SUP] 1 [/SUP]
Affiliations
- PMID: 36897636
- DOI: 10.1097/MPH.0000000000002644
Abstract
Published outcomes for children with cancer with coronavirus disease 2019 (COVID-19) have varied. Outcome data for pediatric oncology patients in Canada, outside of Quebec, have not been reported. This retrospective study captured patient, disease, and COVID-19-related infectious episode characteristics and outcome data for children, 0 to 18 years, diagnosed with a first COVID-19 infection between January 2020 to December 2021 at 12 Canadian pediatric oncology centers. A systematic review of pediatric oncology COVID-19 cases in high-income countries was also undertaken. Eighty-six children were eligible for study inclusion. Thirty-six (41.9%) were hospitalized within 4 weeks of COVID-19; only 10 (11.6%) had hospitalization attributed to the virus, with 8 being for febrile neutropenia. Two patients required intensive care unit admission within 30 days of COVID-19 infection, neither for COVID-19 management. There were no deaths attributed to the virus. Of those scheduled to receive cancer-directed therapy, within 2 weeks of COVID-19, 20 (29.4%) experienced treatment delays. Sixteen studies were included in the systematic review with highly variable outcomes identified. Our findings compared favorably with other high-income country's pediatric oncology studies. No serious outcomes, intensive care unit admissions, or deaths, in our cohort, were directly attributable to COVID-19. These findings support the minimization of chemotherapy interruption after COVID-19 infection.